Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anthrax rPA vaccine
- Development stage
- Phase 2
- Lead developer
- GC Biopharma
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Subcutaneous
01
Overview
Anthrax rPA vaccine is an investigational recombinant protein vaccine consisting of purified recombinant protective antigen (rPA) from Bacillus anthracis designed to elicit high-titer neutralizing antibodies that block protective antigen binding and pore formation required for entry of lethal and edema toxins into host cells. As a next-generation anthrax vaccine, it was developed to improve immunogenicity, consistency of manufacturing, and safety compared with cell-free filtrate anthrax vaccine adsorbed (AVA), and has been evaluated primarily for pre‑ and post‑exposure prophylaxis against inhalational anthrax in adults at risk of exposure to Bacillus anthracis.
- Brand names
- SparVax
- Other names
- recombinant protective antigen anthrax vaccinerPA anthrax vaccinerecombinant protective antigen vaccinerecombinant anthrax vaccinerecombinant protective antigen Bacillus anthracis vaccine
02
Targets
ANTXR2 (Anthrax toxin receptor 2)ANTXR1 (Anthrax toxin receptor 1)PA (Influenza polymerase acidic protein)
Beyond the preview
Go deeper on anthrax rPA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anthrax rPA vaccine.